..

Pharmaceutical Care Clerkship in

Asthma and COPD
()

( )


/
















.
(..)

-
-
-
-
-
-
- /
- /

-
-
-
-
-
-

-/ -/
/
-/ -/ -/

-/ -/ -/

-/ -/ -/


(Pharmaceutical Care Clerkship)

.
/
/


/

. /
.
.
.
.
.
.
(active
learning)

. /
.
/
. / /

.

.
/
. /
/
. /
/

/
) ,

(active learning)

(problem-based learning)

(experiential learning)


/ (project)


/

/

.
.
..

.. /
..
/
.. /
( )
.
..

.. /

.

-
-

. /
. /
-
-
-
-
-
- / /
/

. /
( )
. /

. /

. / (professional skill)
active learning (
/ ) passive learning
. / /
/
(
)

. / /
/

. /
/

. /
/

. /
. /

. /
/
. /
/

. //

. /

. /

. /
/


(Pharmaceutical Care Clerkship in asthma/COPD clinic)

.
/
.
.

. /
. /

.
.
,
GINA 2013
.
mmRC CAT score
GOLD 2013
. (acute
exacerbation)
.

.
/
/

.
.
. /

.
/
.

.
.
.

.
.
.
.

/
.
.
.
.

.

-
/*
-

/
-

/
-
-
-

/
- (journal club)
/
-

/
- (academic in-service)
-

/
-
-

-
-
: *


.
..
..
..
.
.. (-/, -/)
..
(-/, -/ -/)
..
... (Formal case presentation)

... (Academic in-service)

... (Journal Club)

:
-

- formal case presentation

. CC, HPI, PMH, FH, SH, ALL, MH, PE, Lab
Hospital course
.

. > /*

(refilling
system)

-/
-/
. > /
-/
()
. > /
(case
discussion)**
. (formal case presentation) >
-/

-/
-/
. /
>

-
(academic in-service)
. (Journal club)
>
-/

-/
-/

*
** case discussion


................................................................................................................................................
...................................................................................................................................

.
.
.
.
.
.

(refilling system)

()

(case
discussion)**
(formal case presentation)

(academic inservice)
(journal club)

> /*
> /
> /
>
>

>

: *

/
....................................................................................................................................
.......................................................................................................................................................................................
.......................................................................................................................................................................................
.......................................................................
..........................................

--/
/

/...........................................................................................................
................................................................................................................
/

/

(x)
/ ()

/
/

--/
/

/.............................................................................................................
..................................................................................................................

. (
)
.
.

.
. (
)
.
.
.
.
. (
)
. (
)
. (

)
( x )/
/...............................................................................................................................................
.....................................................................................................................................................................................................
.....................................................................................................................................................................................................

.....................................................
(......................................................)

--/

/.........................................................................................................
..............................................................................................................
/

/

(x) /
()

/ /

/ /

/ /

//

//

--/

/...........................................................................................................
................................................................................................................

N/A N/A

.
. ( //
)
. /

.
.

.
. (/
)
.
()
/

.
(subjective & objective data)
.
..
..
(Indication, Efficacy, Safety, Adherence,
Cost)
..
.. /

..
.
..
..

..

.. ///

--/

N/A N/A

.
. /

.
.

.
.
.

.. : pharmacist note,

.. :

.
.

. /
/
( x )/

/.......................................................................................................................................
.............................................................................................................................................................................................
.............................................................................................................................................................................................
.....................................................
(
)

--/

/..........................................................................................................
...............................................................................................................

(x)
/ ()

/
/
(critical point)

/ /

--/

/....................................................................................................
................................................................................................. .........

.
. CC, HPI, PMH, FH, SH, ALL, MH, PE, Lab
.
( x .)/
.
. /
.
(subjective & objective data)
.
..
..
.. (IESAC)
.
..
..
..
.. / ///
( x )/
.
.

( x .)/
.
.
.
. :

( x . )/

N/A

--/

.
. / Pharm D.
.

( x .)/
.
( x )/
( x )/

N/A

/.................................................................................................................................
......................................................................................................................................................................................
......................................................................................................................................................................................

.....................................................
(......................................................)

--/

/ ................................................................................................................
................................................................................... .......................................................

(x)
/ ()

--/

. /
/
/
.
.
.
.
..
.. /

.. / (drop out)
..
-
-
-
..

..

.. (outcome variables & outcome
measurement)
.

.
-
-
-

- /
. /
/
.
.
.
.

N/
A

--/

.:

.
.
/ Pharm D.
.

( x /) /

N/A

/...........................................................................................................................................
.............................................................................................................................................................................................
.............................................................................................................................................................................................

.....................................................
(......................................................)

--

/ ............................................................................. .....................................
...............................................................................................................................................

.
.
.
.
.
.
.

.
.
.
.
.
. :

.
.
. /
Pharm D.
.

( x )/

N/A

/..................................................................................................................................
.......................................................................................................................................................................................
.......................................................................................................................................................................................

.....................................................
(......................................................)


........................................... ..
(demographic of requestor)
.........................................................................................................................................................
................................................
. ............................................... ..........................E-mail address ......................
/

/

............................................................................................................................

(patient-specific question)

......................................................

...............................................................................................................................................
..............................................................................................................................................

.........................................

/
e-mail
website/webboard ....................................................................
(request)
(initial question)
..
..
(background information)
..
..
..
..
(ultimate question)
..
..

 (classification of the ultimate question)

General product information
Adverse effects
Availability of dosage forms
Compounding
Dietary supplement
Dosage recommendations
(general and organ impairment)
Drug interactions
Drug-laboratory interference
Drugs in pregnancy and in
Foreign drug identification
lactation
Geriatric dosage
Identification of product by
recommendations
description of dosage form
Investigational drug information
Compatibility / stability
Method / rate of administration
Pediatric dosage
recommendations
Pharmacokinetics
Pharmacology
(search strategy and conduct on systematic search)*

.
. .....................................
.............................................................................................................................................
.............................................................................................................................................................
. .....................................
.............................................................................................................................................
.............................................................................................................................................................
.
. .....................................
.............................................................................................................................................
.
. .....................................
.............................................................................................................................................
.
.
. .....................................
.............................................................................................................................................
.

. .....................................
.............................................................................................................................................
.
.
. .....................................
.............................................................................................................................................
.
. .....................................
.............................................................................................................................................
.
(keywords)
.
.

.
.
.
.

.
.
.

. ...
.......................................................................................
. ...
.......................................................................................
. ...
.......................................................................................

/
e-mail
web site / web board
............................................................................

.. .
..............................................................

 (Follow up and follow through)

...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
:
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
/...............................................
.....................................................
:
systematic approach
Malone PM, Kier KL, and Stanovich JE. (Eds). Drug Information: a guide for
pharmacists, Third Edition. Singapore: McGraw-Hill, Medical Publishing Division.

/